294 related articles for article (PubMed ID: 22271904)
1. Clinical cardiac safety profile of nilotinib.
Kim TD; le Coutre P; Schwarz M; Grille P; Levitin M; Fateh-Moghadam S; Giles FJ; Dörken B; Haverkamp W; Köhncke C
Haematologica; 2012 Jun; 97(6):883-9. PubMed ID: 22271904
[TBL] [Abstract][Full Text] [Related]
2. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
3. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
Hughes TP; Saglio G; Kantarjian HM; Guilhot F; Niederwieser D; Rosti G; Nakaseko C; De Souza CA; Kalaycio ME; Meier S; Fan X; Menssen HD; Larson RA; Hochhaus A
Blood; 2014 Feb; 123(9):1353-60. PubMed ID: 24335106
[TBL] [Abstract][Full Text] [Related]
4. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
5. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
[TBL] [Abstract][Full Text] [Related]
6. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM
Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466
[TBL] [Abstract][Full Text] [Related]
7. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim TD; Schwarz M; Nogai H; Grille P; Westermann J; Plöckinger U; Braun D; Schweizer U; Arnold R; Dörken B; le Coutre P
Thyroid; 2010 Nov; 20(11):1209-14. PubMed ID: 20929406
[TBL] [Abstract][Full Text] [Related]
8. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
9. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P
Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337
[TBL] [Abstract][Full Text] [Related]
10. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Lobo C; Pasquini R; Clark RE; Hochhaus A; Hughes TP; Gallagher N; Hoenekopp A; Dong M; Haque A; Larson RA; Kantarjian HM;
N Engl J Med; 2010 Jun; 362(24):2251-9. PubMed ID: 20525993
[TBL] [Abstract][Full Text] [Related]
11. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant.
Koren-Michowitz M; le Coutre P; Duyster J; Scheid C; Panayiotidis P; Prejzner W; Rowe JM; Schwarz M; Goldschmidt N; Nagler A
Cancer; 2010 Oct; 116(19):4564-72. PubMed ID: 20572041
[TBL] [Abstract][Full Text] [Related]
12. Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.
Breccia M; Alimena G
Curr Drug Targets; 2009 Jun; 10(6):530-6. PubMed ID: 19519355
[TBL] [Abstract][Full Text] [Related]
13. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.
Giles FJ; Rosti G; Beris P; Clark RE; le Coutre P; Mahon FX; Steegmann JL; Valent P; Saglio G
Expert Rev Hematol; 2010 Dec; 3(6):665-73. PubMed ID: 21091142
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
16. First-line therapy for CML: nilotinib comes of age.
Davies J
Lancet Oncol; 2011 Sep; 12(9):826-7. PubMed ID: 21856227
[No Abstract] [Full Text] [Related]
17. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
[TBL] [Abstract][Full Text] [Related]
18. Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.
Hazarika M; Jiang X; Liu Q; Lee SL; Ramchandani R; Garnett C; Orr MS; Sridhara R; Booth B; Leighton JK; Timmer W; Harapanhalli R; Dagher R; Justice R; Pazdur R
Clin Cancer Res; 2008 Sep; 14(17):5325-31. PubMed ID: 18765523
[TBL] [Abstract][Full Text] [Related]
19. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
Erba HP; Pham DC; Zaiden R; Vu H; Tai S
Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576
[TBL] [Abstract][Full Text] [Related]
20. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
Aichberger KJ; Herndlhofer S; Schernthaner GH; Schillinger M; Mitterbauer-Hohendanner G; Sillaber C; Valent P
Am J Hematol; 2011 Jul; 86(7):533-9. PubMed ID: 21538470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]